Teleflex TFX NYSE · Healthcare · United States
$155.00 +1.21% +$1.85
Summary
43 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 14 USD is left as net profit.
- It bought back its own shares for $300.0M in the last fiscal year, 4.9% of its market value.
- Analysts expect revenue to grow by 14% this fiscal year.
What to watch
- Revenue fell by 11% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- Repaying its net debt would take 3.9 years of operating profit.
- It earns only 3.2 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 19.8 USD for 1 USD of yearly profit. Over the last five years it was 54.5 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 4.7% a year over 5 years. Over the last 3 years it fell by 11% a year. For the next fiscal year analysts expect revenue to grow by 14%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 42 USD
- Research and development 8.0 USD
- Sales and administration 40 USD
- Taxes and other -3.8 USD
- Net profit 14 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.5 USD
Out of every 100 USD of revenue, 14 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.3 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.89%
- Paid out of profit
- 18%
You receive $1.36 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 16
- Hold 13
- Sell 0
Today's price within the analysts' price targets
The average target of $156.75 is 1.1% above today's price. 55% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Vascular Access 46%
- Interventional 33%
- Surgical 21%
- Other 0.5%
By region
- UNITED STATES 63%
- EMEA 26%
- Asia 12%
Vascular Access brings in 46% of revenue. Interventional grew fastest, by 11% a year.
Segments in detail